Transitioning psoriasis patients to adalimumab following a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study

被引：0

作者：

Strober, B. ^{[1
]}

Poulin, Y. ^{[2
]}

Kerdel, F. ^{[3
]}

Langley, R. ^{[4
]}

Menter, A. ^{[5
]}

Papp, K. ^{[6
]}

Gu, Y. ^{[7
]}

Okun, M. ^{[7
]}

机构：

[1] NYU, Sch Med, New York, NY USA

[2] Ctr Dermatol Quebec Metropolitain, Quebec City, PQ, Canada

[3] Florida Acad Dermatol Ctr, Miami, FL USA

[4] Dalhousie Univ, Halifax, NS, Canada

[5] Baylor Psoriasis Res Inst, Dallas, TX USA

[6] Clin Res, Waterloo, ON, Canada

[7] Abbott Labs, Abbott Pk, IL 60064 USA

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2010年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P021

引用

页码：9 / 9

页数：1

共 50 条

[11] The effects of adalimumab on C-reactive protein and sleep in moderate to severe psoriasis patients with suboptimal response to etanercept, methotrexate, or phototherapy: Subanalysis of the PROGRESS study
Strober, Bruce
Goldblum, Orin
Wang, Yuzhen
Poulin, Yves
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB215 - AB215
[12] Open-label, prospective evaluation of adalimumab for psoriasis patients who were nonresponders to etanercept
Martyn-Simmons, C.
Green, E.
Ash, G.
Groves, R.
Smith, C. H.
Barker, J. N. W. N.
BRITISH JOURNAL OF DERMATOLOGY, 2008, 159 (06) : 1425 - 1426
[13] Efficacy and safety of etanercept in the treatment of recalcitrant psoriasis: An open-label, retrospective, observational study in Taiwan
Wu, Yi-Fang
Shin, Yi-Chin
Yang, Chih-Hsun
Huang, Yu-Huei
DERMATOLOGICA SINICA, 2013, 31 (02) : 49 - 53
[14] Efficacy and safety of efalizumab for nail psoriasis: Results of an open-label, multicenter study
Rich, Phoebe
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (02) : AB130 - AB130
[15] An Open-Label, Prospective Cohort Pilot Study to Evaluate the Efficacy and Safety of Etanercept in the Treatment of Moderate to Severe Plaque Psoriasis in Patients Who Have Not Had an Adequate Response to Adalimumab
Vender, Ronald
JOURNAL OF DRUGS IN DERMATOLOGY, 2011, 10 (04) : 396 - 402
[16] Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab
Bagel, J.
Tyring, S.
Rice, K. C.
Collier, D. H.
Kricorian, G.
Chung, J.
Iles, J.
Stolshek, B. S.
Kaliyaperumal, A.
Papp, K. A.
BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (02) : 411 - 418
[17] Efficacy and safety of weekly adalimumab in psoriasis patients with a less than PASI 50 response to 40 mg every other week: results from an open-label extension study
Leonardi, C.
Menter, A.
Gu, Y.
Okun, M.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2010, 24 : 9 - 10
[18] Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation
Martyn-Simmons, C. L.
Green, L.
Ash, G.
Groves, R. W.
Smith, C. H.
Barker, J. N. W. N.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2009, 23 (12) : 1394 - 1397
[19] Safety and efficacy of etanercept treatment in children and adolescents with plaque psoriasis: 96-week results of open-label extension study
Paller, Amy
Pariser, David
Siegfried, Elaine
Kricorian, Gregory
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (03) : AB11 - AB11
[20] Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy
Strober, B. E.
Poulin, Y.
Teller, C.
Wang, Y.
Williams, D. A.
Goldblum, O. M.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2014, 28 (12) : 1701 - 1706

← 1 2 3 4 5 →